2 results about "Reproductive system disease" patented technology

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

This invention provides 3-amino-4-(piperazin-1-yl)benzamide derivatives, pharmaceutical compositions comprising them, methods for their preparation, and applications. These compounds act as PLAGL2 protein inhibitors, playing a significant role in various diseases, including but not limited to pain, inflammation, immune dysfunction, neurological and psychiatric disorders, respiratory diseases, urinary system diseases, reproductive system diseases, embryonic developmental abnormalities, cell metabolic disorders, differentiation problems, and viral infections. PLAGL2 plays a particularly positive role in the occurrence, development, and prognosis of malignant tumors such as liver cancer, lung cancer, and glioma. The compounds of this invention exhibit excellent PLAGL2 inhibitory activity. This invention also provides the compounds comprising the pharmaceutically acceptable salts thereof, pharmaceutically acceptable carriers or excipients, and methods for their preparation.